report by BlackRock
Results for ""
Retirement
Taking Stock of Emergency Savings Account Options
This piece is approved to use with clients.
The events of the past year have reinforced the importance of being financially prepared for unexpected emergencies. Retirement Director Ben Rizzuto discusses some of the options – both inside and outside of retirement plans – that are available for plan sponsors and business owners to help employees build up adequate savings.
Macroeconomic & Geopolitical
Japan Equities Outlook: What Can Tuna Auctions Tell Us About Future Market Trends?
This piece is approved to use with clients.
Junichi Inoue, Head of Japanese Equities, discusses why the Japanese stock market performed well last year despite its cyclicality and shares his outlook for a recovery in 2021.
Sustainable Investing
ESG in 2021: Closing the Expectations Gap
This piece is approved to use with clients.
Antony Marsden, Head of Governance and Responsible Investment, explores key themes related to Environmental, Social and Governance (ESG) investing in 2021, including why a rethink on ratings is necessary to align expectations with reality.
Active/Passive Management
Active ETFs Are Here to Stay
This piece is approved to use with clients.
Head of Exchange-Traded Products Nick Cherney discusses the driving forces behind the growth of the exchange-traded fund (ETF) industry and why active ETFs are capturing a larger share of the overall market.
Sustainable Investing
Global Sustainable Equity: News and Opportunities
This piece is approved to use with clients.
Reflecting on the last quarter of 2020 and looking ahead to the opportunities in the world of sustainability.
Sustainable Investing
Influencing for good: 20 years of engagement
This piece is approved to use with clients.
The way investors conduct engagement has transformed. From a niche approach largely confined to mission-orientated investors, engagement is now a mainstream investor activity. The success of the Climate Action 100+ initiative in bringing together investors, representing close to US$40 trillion in assets, shows how far we have come.
Sustainable Investing
ESG Viewpoint – COVID-19 and the pharmaceutical industry
This piece is approved to use with clients.
Public trust in the pharmaceutical industry has eroded. The pandemic provides drug-makers a chance to begin re-building their reputation – but only if they prioritise socially responsible practices.